IND of Sirotinib, anti-oncology new drug, is approved by CFDA
2015-07-17 14:36:34 Author:admin
      IND filing of Sirotinib (XZP-5491), submitted at the end of June 2015, has been approved by CFDA (The filing numbers are CXHL1501499 and CXHL1501499). 
      The second anti-cancer new drug developed by XuanZhu, Sirotinib is a new generation, irreversible pan-Her inhibitor for the treatment of advanced cancers, including esophageal, gastric and lung carcinoma. Our comprehensive preclinical studies demonstrate that Sirotinib is potentially effective in a broad range of cancers, especially esophageal squamous cell carcinoma (ESCC), which is most common in China. We are confident that Sirotinib will be a success on the way to the market, bringing greatest benefit to Chinese patients and maximal value to Sihuan and XuanZhu.-金沙网站-金沙娱城js3311


Email | Terms of Use | | Contact us |
Copyright © 2014 Sihuan Pharmaceutical Holdings Group Ltd. All rights reserved 鲁ICP备09030169号

金沙娱城js3311 轩竹微信民众号